Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study.

G Sandrini1, M Färkkilä, G Burgess

  • 1University Centre for Adaptive Disorders and Headache, IRCCSC. Mondino Foundation, Pavia, Italy. gsandrini@unipv.it

Neurology
|October 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety.

Frontiers in pharmacology·2023
Same author

Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis.

Microbiology spectrum·2023
Same author

Pain and agitation treatment in severe dementia patients: The need for Italian Mobilization-Observation-Behavior-Intensity-Dementia (I-MOBID2) pain scale translation, adaptation and validation with psychometric testing.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2022
Same author

Anodal transcranial direct current stimulation in chronic migraine and medication overuse headache: A pilot double-blind randomized sham-controlled trial.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2020
Same author

Molecular evidence for horizontal transmission of chelonid alphaherpesvirus 5 at green turtle (Chelonia mydas) foraging grounds in Queensland, Australia.

PloS one·2020
Same author

Community exchange and time currencies: a systematic and in-depth thematic review of impact on public health outcomes.

Public health·2019
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Eletriptan, at 40 mg and 80 mg, demonstrated superior efficacy and patient acceptability compared to sumatriptan for acute migraine treatment. Both medications were well-tolerated, offering effective relief for migraineurs.

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Migraine is a common neurological disorder impacting millions globally.
  • Triptans are a class of drugs used for acute migraine treatment.
  • Comparing different triptan formulations and dosages is crucial for optimizing patient care.

Purpose of the Study:

  • To evaluate and compare the efficacy of oral eletriptan (40 mg and 80 mg) against oral sumatriptan (50 mg and 100 mg).
  • To assess both early (1-hour) and standard (2-hour) headache response rates.
  • To determine functional improvement and patient acceptability.

Main Methods:

  • A randomized, placebo-controlled trial involving 1,008 patients with a history of migraine.
  • Participants were assigned to receive placebo, eletriptan (40 mg or 80 mg), or sumatriptan (50 mg or 100 mg) to treat up to three migraine attacks.

Related Experiment Videos

  • Primary endpoint: 1-hour headache response; Secondary endpoint: 2-hour headache response.

    • Main Results:

    • Eletriptan 80 mg showed a significantly higher 1-hour headache response rate than sumatriptan 50 mg (p < 0.05).
    • Both eletriptan doses (40 mg and 80 mg) were superior to sumatriptan at 2 hours for headache response and pain relief (p < 0.05).
    • Eletriptan 40 mg demonstrated superior functional improvement (p < 0.005), and both eletriptan doses had higher patient acceptability than sumatriptan 50 mg (p < 0.05).

    Conclusions:

    • Oral eletriptan (40 mg and 80 mg) is an effective, safe, and well-tolerated treatment for acute migraine.
    • Eletriptan provides a consistent and superior response compared to sumatriptan, particularly in terms of functional improvement and patient acceptability.
    • The study supports eletriptan as a valuable option for the acute management of migraine.